Susquehanna International Group
LRMR icon

Susquehanna International Group’s Larimar Therapeutics LRMR Stock Holding History

Susquehanna International Group’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$630K Sell
140,060
-112,723
-45% -$451K ﹤0.01% 9067
2025
Q4 		$963K Buy
252,783
+181,360
+254% +$705K ﹤0.01% 7280
2025
Q3 		$231K Sell
71,423
-178,872
-71% -$671K ﹤0.01% 10677
2025
Q2 		$723K Buy
250,295
+88,393
+55% +$205K ﹤0.01% 8280
2025
Q1 		$348K Buy
161,902
+94,323
+140% +$298K ﹤0.01% 9727
2024
Q4 		$262K Buy
67,579
+46,722
+224% +$308K ﹤0.01% 10126
2024
Q3 		$137K Sell
20,857
-31,123
-60% -$250K ﹤0.01% 10824
2024
Q2 		$377K Sell
51,980
-6,142
-11% -$47K ﹤0.01% 8938
2024
Q1 		$441K Buy
58,122
+47,747
+460% +$372K ﹤0.01% 8815
2023
Q4 		$47.2K Buy
+10,375
New +$35K ﹤0.01% 11735
2023
Q3 		– Sell
-12,818
Closed -$48.5K – 12542
2023
Q2 		$40.1K Sell
12,818
-167,135
-93% -$682K ﹤0.01% 11420
2023
Q1 		$815K Buy
+179,953
New +$940K ﹤0.01% 7358
2022
Q4 		– Sell
-15,709
Closed -$50K – 13138
2022
Q3 		$50K Buy
+15,709
New +$39.4K ﹤0.01% 12202
2022
Q2 		– Sell
-55,366
Closed -$224K – 13506
2022
Q1 		$224K Sell
55,366
-43,974
-44% -$288K ﹤0.01% 10965
2021
Q4 		$1.07M Buy
99,340
+29,523
+42% +$328K ﹤0.01% 7118
2021
Q3 		$805K Buy
+69,817
New +$838K ﹤0.01% 8114
2021
Q2 		– Sell
-18,810
Closed -$275K – 12963
2021
Q1 		$275K Buy
+18,810
New +$342K ﹤0.01% 10782
2018
Q2 		– Sell
-8,520
Closed -$724K – 10041
2018
Q1 		$762K Buy
8,520
+7,452
+698% +$632K ﹤0.01% 5784
2017
Q4 		$59K Buy
+1,068
New +$48.1K ﹤0.01% 8868
2017
Q3 		– Sell
-6,672
Closed -$281K – 9277
2017
Q2 		$281K Buy
6,672
+5,795
+661% +$296K ﹤0.01% 7699
2017
Q1 		$49K Sell
877
-2,646
-75% -$131K ﹤0.01% 8595
2016
Q4 		$134K Buy
3,523
+1,260
+56% +$51.1K ﹤0.01% 8925
2016
Q3 		$90K Buy
2,263
+493
+28% +$22.4K ﹤0.01% 7977
2016
Q2 		$127K Sell
1,770
-3,380
-66% -$267K ﹤0.01% 7907
2016
Q1 		$413K Sell
5,150
-1,871
-27% -$148K ﹤0.01% 6729
2015
Q4 		$530K Buy
7,021
+3,661
+109% +$588K ﹤0.01% 6650
2015
Q3 		$1.29M Buy
3,360
+2,678
+393% +$1.21M ﹤0.01% 5160
2015
Q2 		$283K Sell
682
-14
-2% -$5.86K ﹤0.01% 8637
2015
Q1 		$331K Buy
+696
New +$330K ﹤0.01% 7792

Other funds holding LRMR

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Susquehanna International Group's LRMR Position: Q1 2026 in Review

Susquehanna International Group reduced its Larimar Therapeutics (LRMR) stake by 45% in Q1 2026, selling an estimated $451K and leaving 140,060 shares worth $630K. The position accounts for ﹤0.01% of the portfolio, ranked #9067.

Susquehanna International Group first reported a position in LRMR in Q1 2015 and has held it in 29 quarters since. The position peaked at $1.29M in Q3 2015. 162 funds tracked by Wall St. Rank hold LRMR as of Q1 2026.

  • Susquehanna International Group held 140,060 shares of Larimar Therapeutics worth $630K as of Q1 2026.
  • Susquehanna International Group sold 112,723 Larimar Therapeutics shares in Q1 2026, an estimated $451K.
  • Larimar Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #9067 holding.
  • Susquehanna International Group first reported a position in Larimar Therapeutics in Q1 2015 and has held it in 29 quarters since.
  • Susquehanna International Group's Larimar Therapeutics position peaked at $1.29M in Q3 2015.
  • 162 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.